Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
暂无分享,去创建一个
Mark Jit | Marc Brisson | M. Jit | R. Hutubessy | M. Brisson | Allison Portnoy | Raymond Hutubessy | A. Portnoy
[1] X. Castellsagué,et al. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. , 2014, Vaccine.
[2] M. Robson,et al. A Model for Enhancing Evidence-Based Capacity to Make Informed Policy Decisions on the Introduction of New Vaccines in the Americas: Paho's Provac Initiative , 2007, Public health reports.
[3] N. Broutet. Comprehensive Cervical Cancer Control: Strategies and Guidelines , 2013 .
[4] T. Edejer,et al. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis. , 2009, Vaccine.
[5] M. Boily,et al. Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries , 2009, Public Health Genomics.
[6] C. Marra,et al. The Cost Effectiveness of Human Papillomavirus Vaccines , 2012, Drugs.
[7] H. Cubie,et al. Human papillomavirus vaccine introduction--the first five years. , 2012, Vaccine.
[8] S. Goldie,et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. , 2008, Vaccine.
[9] M. Jit,et al. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. , 2013, Vaccine.
[10] M. Seoud,et al. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA). , 2013, Vaccine.
[11] J. Berkhof,et al. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. , 2013, Vaccine.
[12] P. Lopalco,et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[13] D. Koleva,et al. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review , 2011, Internal and emergency medicine.
[14] P. Maisonneuve,et al. Carcinoma of the cervix uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[15] J. Berkhof,et al. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts , 2013, BMC Medicine.
[16] S. Garland,et al. Human Papillomavirus Vaccines , 2010, Drugs.
[17] Who,et al. Human papillomavirus vaccines: WHO position paper. , 2009, Biologicals : journal of the International Association of Biological Standardization.
[18] Alan D. Lopez,et al. Global burden of disease and risk factors , 2006 .
[19] A. Rothberg. Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2008 .
[20] P. Maisonneuve,et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[21] Alan D. Lopez,et al. The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001 -- Global Burden of Disease and Risk Factors , 2006 .
[22] S. Franceschi,et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication , 2011, International journal of cancer.
[23] P. Bonanni,et al. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. , 2009, Vaccine.
[24] C. Marra,et al. Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine , 2012, PharmacoEconomics.
[25] Rob Baltussen,et al. Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2003 .
[26] H. Cubie,et al. Corrigendum to: “Human Papillomavirus Vaccine Introduction – The First Five Years” [Vaccine 30 (Suppl. 5) (2012) F139–F148] , 2014 .
[27] Jacques Ferlay,et al. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .
[28] Jane J. Kim,et al. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. , 2013, Vaccine.
[29] Marc Brisson,et al. Modeling cervical cancer prevention in developed countries. , 2008, Vaccine.